Formulation development of Freeze Dried Inhalable microparticles of Hydroxychloroquine

COVID-19 is a new corona virus disease respiratory illness which is severe and potentially fatal which can cause mortality in severe cases due to alveolar collapse. HCQ could be effectively used in the treatment of SARS-CoV pneumonia. However, the major problems of oral treatment with HCQ can cause possible severe side effects and toxicity; hepatic first-pass metabolism and drug accumulation in liver. Inhalable HCQ microparticles pass through airway & prevent replication of virus effectively & surfactants maintain alveolar capacity. Administration of formulation using an autohaler (Inhaler) produces long duration of action in lungs and further absorption in systemic circulation avoiding first pass metabolism. In turn, inhalable HCQ microparticles could be an important tool for management of acute respiratory distress syndrome (ARDS) in COVID as well as in emergency care clinical team.


Meet the Team

  • Ms. Rupanshi Grover

    Student (CCP)
    Chitkara University, Punjab
  • Dr. Neelam Sharma

    Associate Professor (CCP)
    Chitkara University, Punjab
  • Dr. Sukhbir Singh

    Associate Professor (CCP)
    Chitkara University, Punjab
  • Dr. Sandeep Arora

    Director (CCP)
    Chitkara University, Punjab

Contact Information

Ms. Rupanshi Grover
Email –
Mobile – +91 9855348586